Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Proliferative lupus nephritis (LN) is a severe pathological type of systemic lupus erythematosus with a high risk of progression to chronic kidney disease and end-stage renal disease. The prognosis of patients with proliferative LN has improved with advancements in treatment regimens. However, more effective molecular targeted therapies are still needed. This study aimed to evaluate the efficacy and safety of two novel biologics, telitacicept and belimumab, in the treatment of proliferative LN.
Twenty-eight individuals diagnosed with proliferative LN (class III/IV±V) were retrospectively enrolled at the Second Affiliated Hospital of Hainan Medical University between January 2021 and May 2025 and received either telitacicept (n=18) or belimumab (n=10) in conjunction with standard therapy for more than 24 weeks. The renal response rates were the evaluated outcome.
A total of 28 patients were enrolled, with 18 receiving telitacicept and 10 receiving belimumab. At 8 weeks, the telitacicept group presented a greater renal remission rate, with 8 patients (44.4%) achieving a complete renal response (CRR), 7 patients (38.9%) achieved partial renal response (PRR), and 3 patients (16.7%) showed no renal response (NRR). In contrast, only 6 patients (60%) achieved PRR in the Belimumab group. The renal remission rate at 8 weeks was significantly higher in the Telitacicept group compared to the Belimumab group (p=0.04). The telitacicept group also demonstrated greater improvements in the SLEDAI-2K score and complement C3 level. At 24 weeks, 72.2% of the telitacicept group achieved a CRR, whereas 60% of the belimumab group achieved a CRR, with no significant difference in renal response rates. Glucocorticoid and immunosuppressant use was successfully reduced in both groups. Additionally, both groups showed improvements in clinical parameters, but no significant difference was noted at 24 weeks.
Telitacicept may lead to earlier renal and immunologic remission in patients with proliferative LN than belimumab, potentially reducing the need for glucocorticoids and immunosuppressants. Further validation in larger studies is needed.
